Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QL1706 + lenvatinib
- Development stage
- Phase 2
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Oral
01
Overview
QL1706 + lenvatinib is a combination therapy under investigation for the treatment of various cancers. QL1706 is an investigational bifunctional antibody that combines the activity of both PD-1 and CTLA-4 antibodies, functioning as a dual immune checkpoint inhibitor to enhance antitumor immune responses[1][2][3]. Lenvatinib is an oral small molecule receptor tyrosine kinase inhibitor that targets multiple kinases involved in tumor angiogenesis and proliferation, including VEGFR1–3, FGFR1–4, PDGFRα, KIT, and RET[6][8]. The combination aims to leverage both immune modulation (via checkpoint inhibition) and antiangiogenic/antiproliferative effects (via kinase inhibition). Clinical trials are ongoing for several solid tumors including non-small cell lung cancer (NSCLC), cervical cancer, hepatocellular carcinoma (HCC), among others[2][3][7].
- Other names
- lenvatinib
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on QL1706 + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QL1706 + lenvatinib.